These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25096996)

  • 1. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
    Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
    Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
    Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
    Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Ai Z; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
    Zheng L; Li L; Lu Y; Jiang F; Yang XA
    Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
    Rao YM; Shi HR; Ji M; Chen CH
    J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
    Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
    Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.
    Mao D; Che J; Han S; Zhao H; Zhu Y; Zhu H
    Mol Med Rep; 2015 Nov; 12(5):6635-41. PubMed ID: 26299671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
    Jiang L; Luo RY; Yang J; Cheng YX
    Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
    Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
    Yan XD; Pan LY
    Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.